| Literature DB >> 1874601 |
J P Crown1, S Gulati, D J Straus, J Kolitz, R Heelan, J O'Brien, B J Lee, C Portlock, J Bertino.
Abstract
As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease. An overall partial response rate of 41% was observed. Although useful responses were seen, the absence of complete remissions is disappointing.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1874601 DOI： 10.1007/bf00175086
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850